If future multi-center studies with larger sample sizes can further validate these results, biomarkers such as SOD and PRX4 may emerge as predictive indicators for patients with colorectal cancer, thereby supporting the advancement of precision medicine. The gene discussed is SOD1; the disease is colorectal cancer.